Se recomienda +
Pembrolizumab, with carboplatin and paclitaxel + NSCLC + Adults
National Institute for Health and Clinical Excellence (NICE)
Current treatment for untreated metastatic squamous NSCLC is usually platinum-based combination chemotherapy (standard chemotherapy) for people whose tumours express PD‑L1 with a tumour proportion score of lower than 50%, or pembrolizumab monotherapy for people whose tumours express PD‑L1 with a tumour proportion score of 50% or higher.
The main clinical evidence for pembrolizumab with carboplatin